This week’s episode will be focusing on Diffuse Large B-Cell Lymphoma (DLBCL). We will go all the important details on this aggressive NHL which can be highly curable. We have some new changes since we last covered this topic in 2022 including a new category 1 option for advanced DLBCL
Jun 29
Transitioning from Fellow to Attending with Dr. Laura Vater
This week’s episode we have a very special guest, friend and colleague Dr. Laura Vater joining us to talk about one of the biggest transitions in medicine—moving from fellow to attending.Dr Vater is a GI oncologist at IU, writer, and speaker. She focuses on the dignity of patient ... Show More
19m 7s
Jan 2023
Episode 044: Myeloma Series, Pt.5 - Myeloma Treatment
<p class="" style="white-space:pre-wrap;">In this continuation of our myeloma series, we build on our prior discussion about myeloma pharmacology, this time discussing how to select the optimal regimen for treatment of our patients.</p><p class="" style="white-space:pre-wrap;">Co ... Show More
34m 19s
Dec 2024
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show More
20m 5s
Jan 2023
Episode 043: Myeloma Series, Pt.4 - Myeloma Pharmacology
<p class="" style="white-space:pre-wrap;">In this continuation of our myeloma series, we begin our discussion about treatment options for multiple myeloma, focusing first on pharmacology. We are so thrilled to have a special guest, Kathryn Maples, PharmD, BCOP who is a clinical p ... Show More
48m 42s
Sep 2024
Episode 116: AML Series, Pt. 2 - MDS/AML Diagnosis and Risk Stratification
<p>In this week’s episode, we discuss the diagnostic criteria and risk stratification for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), building on our discussion from last week. Also, if you have not done so, please do check out our hemepath series to ensure y ... Show More
31m 56s
<p class="" style="white-space:pre-wrap;">We continue our myeloma series, transitioning our discussion from autologous stem cell transplant to maintenance therapy for myeloma.</p><p class="" style="white-space:pre-wrap;">Content:</p><p class="" style="white-space:pre-wrap;">- Why ... Show More
